# Acceleris Capital

> Acceleris Capital is a VC fund backing Biotechnology and Health Care. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Manchester, United Kingdom
- Total investments: 16
- Last investment: Sep 2022
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/acceleris-limited
- X (Twitter): https://www.twitter.com/acceleris
- Website: http://acceleris.com/
- Facebook: https://www.facebook.com/acceleris

Acceleris Capital is a VC fund in Manchester focused on Biotechnology and Health Care. Acceleris Capital arrange new capital for SME's and have direct investment in several technology based companies. They serve funding, investment and advisory needs from their office in central Manchester. Their USP is taking companies from startup through to exit, not only adding comfort to their introduced investors, but also providingongoing mentoring and support at the most crucial time of an SMEs lifecycle.

## Contacts

5 contacts available for Acceleris Capital. Shizune tracks 1 team members at Acceleris Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/acceleris-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Venture - Series Unknown | $1.5M–$4.2M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 31% |
| Health Care | 3 | 19% |
| Manufacturing | 3 | 19% |
| Pharmaceutical | 3 | 19% |
| Farming | 2 | 13% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 6 | 38% |
| Seed | 4 | 25% |
| Venture - Series Unknown | 3 | 19% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 9 | 56% |
| Australia | 1 | 6% |
| United States | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Norman Molyneux | Managing Director | 3 | https://shizune.co/investors/profile/norman-molyneux |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Reacta Healthcare | Reacta Healthcare develops diagnostic solutions and challenge meals for food allergy testing and clinical research. | $1.5M | Venture - Series Unknown | Sep 12, 2022 |  |
| Power Roll | Power Roll Limited was established to develop and commercialise its highly innovative proprietary energy storage and energy generation technologies. Power Roll technologies exhibit a range of significant benefits and advantages over existing technologies such that it is likely that the technology can prove extremely disruptive across a wide rangeof applications and markets. Power Roll has a strong intellectual property portfolio, with 15 different patent families already established. These patent families are spread across all three technologies with five directly related to Energy Storage, nine related to Solar PV and one focusing on the nano-barrier technology. | $4.2M | Venture - Series Unknown | Feb 19, 2021 |  |
| Reacta Biotech | Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP). | $1.5M | Venture - Series Unknown | Apr 21, 2020 |  |
| Reacta Healthcare | Reacta Healthcare develops diagnostic solutions and challenge meals for food allergy testing and clinical research. | $1.5M | Venture - Series Unknown | Apr 21, 2020 |  |
| Vertical Future | Vertical Future is a technology company focused on building a better, more sustainable urban food production and supply system. | $5.2M | Seed | Oct 08, 2019 |  |
| ADC Biotechnology | ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs. | $7.9M |  | Sep 25, 2017 |  |
| Redag Crop Protection | The novel and broadly validated Redox Switch™ approach allows Redag Crop Protection to begin with best in class crop protection products and find new intellectual property that supports development of novel agrochemicals. These properties have shorter less costly development cycles bringing rapid innovation to the industry. There is a growing needfor new products as older ones are withdrawn either for safety reasons or because resistance has developed that reduces performance. | $2M |  | Sep 19, 2017 |  |
| Apex Molecular | Apex Molecular a leading provider of specialist chemistry services to the pharmaceutical, biotechnology and applied chemistry sectors. |  |  | Oct 06, 2016 |  |
| Redag Crop Protection | The novel and broadly validated Redox Switch™ approach allows Redag Crop Protection to begin with best in class crop protection products and find new intellectual property that supports development of novel agrochemicals. These properties have shorter less costly development cycles bringing rapid innovation to the industry. There is a growing needfor new products as older ones are withdrawn either for safety reasons or because resistance has developed that reduces performance. | $2M |  | Mar 03, 2016 |  |
| Evgen Pharma | Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers haveidentified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products. | $2M |  | Sep 10, 2015 |  |

10 of 16 investments shown.

## Co-investors
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund, 4 deals together
- [Moulton Goodies](https://shizune.co/investors/profile/moulton-goodies) — VC Fund, 3 deals together
- [Catapult Ventures](https://shizune.co/investors/profile/catapult-venture-managers) — VC Fund, 1 deal together
- [Earthworm Group](https://shizune.co/investors/profile/earthworm-group) — VC Fund, 1 deal together
- [Enterprise Ventures](https://shizune.co/investors/profile/enterprise-ventures-limited) — VC Fund, 1 deal together
- [GM&C Life Sciences Fund](https://shizune.co/investors/profile/gm-c-life-sciences-fund) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotech VC Funds in United Kingdom](https://shizune.co/investors/biotech-vc-funds-united-kingdom)
- [Agriculture (agtech) Investors in United Kingdom](https://shizune.co/investors/agriculture-agtech-investors-united-kingdom)
- [Agriculture (agtech) VC Funds in United Kingdom](https://shizune.co/investors/agriculture-agtech-vc-funds-united-kingdom)
- [Agriculture (agtech) Investors in United Kingdom](https://shizune.co/investors/agriculture-agtech-investors-united-kingdom)
- [Agriculture (agtech) VC Funds in United Kingdom](https://shizune.co/investors/agriculture-agtech-vc-funds-united-kingdom)

## FAQ

### What does Acceleris Capital invest in?

Acceleris Capital invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Funding Round and Seed stage. Most of the 16 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Acceleris Capital's check size?

Acceleris Capital typically joins rounds of $1.5M–$4.2M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Acceleris Capital participates in.

### How do I contact Acceleris Capital?

Public channels for Acceleris Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Acceleris Capital?

The team at Acceleris Capital includes Norman Molyneux (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co